*The search scope is limited to the products and news section of this site
*The search scope is limited to the products and news section of this site
On 9 November, according to the disclosure from the Hong Kong Stock Exchange (HKEX), Genuine Biotech Limited (hereinafter referred to as "Genuine Biotech") has submitted its application for listing on the Main Board of HKEX, advancing an important step in the company's development.
The next-generation "small molecule drug" + "novel toxin" dual-platform project independently developed by Genuine Biotech will be presented at the AACR annual meeting as "Late-Breaking Research".
Recently, at the BIOCHINA 2025 10th International Convention, the BIOCHINA Awards 2024 List was announced. Genuine Biotech, with its breakthrough R&D achievements, won the "2024 Innovation Breakthrough Enterprise Award".
On Feb. 2, Wang Zhaoyang, founder of Genuine Biotech, was invited to the new year government-enterprise exchange conference held by the CPC Henan Province Committee and the People's Government of Henan Province.
Copyright © 2022 河南真实生物科技有限公司 All Rights Reserved 京ICP备2021026784号-1
